Generex Biotechnology Corporation - Product Pipeline Review - 2014

Generex Biotechnology Corporation - Product Pipeline Review - 2014


January 31, 2014
45 Pages - SKU: GMD5201738
License type:
Online Download      US $1,500.00
Site License      US $3,000.00
Global Site License      US $4,500.00
Generex Biotechnology Corporation - Product Pipeline Review - 2014

Summary

Global Market Direct’s pharmaceuticals report, “Generex Biotechnology Corporation - Product Pipeline Review - 2014” provides data on the Generex Biotechnology Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Generex Biotechnology Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Generex Biotechnology Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Generex Biotechnology Corporation - Brief Generex Biotechnology Corporation overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Generex Biotechnology Corporation human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Generex Biotechnology Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Generex Biotechnology Corporation’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Generex Biotechnology Corporation’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Generex Biotechnology Corporation in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Generex Biotechnology Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Generex Biotechnology Corporation.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Generex Biotechnology Corporation and identify potential opportunities in those areas.



More Pharmaceuticals Company reports by Global Markets Direct

Wroclawskie Centrum Badan EIT+ Sp. z o.o. - Product Pipeline Review - 2014 by Global Markets Direct
Wroclawskie Centrum Badan EIT+ Sp. z o.o. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Wroclawskie Centrum Badan EIT+ Sp. z o.o. - Product Pipeline ...
Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014 by Global Markets Direct
Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014’, provides an overview of the ...
Orphazyme ApS - Product Pipeline Review - 2014 by Global Markets Direct
Orphazyme ApS - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Orphazyme ApS - Product Pipeline Review - 2014’, provides an overview of the Orphazyme ApS’s ...
Istituto Italiano di Tecnologia - Product Pipeline Review - 2014 by Global Markets Direct
Istituto Italiano di Tecnologia - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Istituto Italiano di Tecnologia - Product Pipeline Review - 2014’, provides an overview ...
See all reports like this >>